Literature DB >> 12027554

Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3.

Matti Ahonen1, Risto Ala-Aho, Andrew H Baker, Sarah J George, Reidar Grénman, Ulpu Saarialho-Kere, Veli-Matti Kähäri.   

Abstract

We have studied the effect of a newly identified tumor suppressor tissue inhibitor of metalloproteinases- 3 (TIMP-3) on the growth of human melanoma and squamous-cell carcinoma (SCC). Adenoviral delivery of the TIMP-3 gene to human melanoma (A2058) and SCC (UT-SCC-7) cells ex vivo inhibited tumorigenesis after subcutaneous (s.c.) injection of the infected cells into SCID/SCID mice. Three daily consecutive intratumoral injections of 1.4x10(9) plaque-forming units (pfu) of TIMP-3 adenovirus (RAdTIMP-3) inhibited the growth of preestablished melanoma and SCC xenografts in SCID/SCID mice, whereas growth of control virus-injected tumors was not affected. The antitumor effect of RAdTIMP-3 was obtained with in vivo adenoviral transduction efficiency of 8-10%, and it was more potent than that of adenovirally delivered p53. Adenovirusmediated expression of TIMP-3 potently reduced gelatinolytic activity, increased the number of apoptotic cells, and inhibited vascularization of melanomas. Escalation of the adenoviral dose to three rounds of three daily consecutive injections with 1.4x10(9) pfu of RAdTIMP-3 every 6 days entirely inhibited growth of injected melanomas for 32 days. Mixing RAdTIMP-3-infected A2058 cells with uninfected cells in 1:1 ratio in culture resulted in death of all cells in 96 hours. Adenovirally delivered TIMP-3 was also expressed by A2058 cells in soluble form into the culture medium, where it exerted a cytotoxic effect on uninfected A2058 cell cultures after relocating to the cell layer. These results identify TIMP-3 as a novel type of secreted tumor suppressor, which has antiinvasive, antiangiogenic, and proapoptotic effects in vivo, and which displays a potent bystander effect validating further exploration of its applicability in human cancer gene therapy. (c)2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027554     DOI: 10.1006/mthe.2002.0606

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  13 in total

1.  Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

Authors:  R Gan; Y Yang; X Yang; L Zhao; J Lu; Q H Meng
Journal:  Cancer Gene Ther       Date:  2014-06-13       Impact factor: 5.987

2.  Expression of metalloproteases and their inhibitors by tumor and stromal cells in ductal carcinoma in situ of the breast and their relationship with microinvasive events.

Authors:  L O González; S González-Reyes; S Junquera; L Marín; L González; J M Del Casar; J M González; Francisco Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-03       Impact factor: 4.553

Review 3.  "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Authors:  Balveen Kaur; Timothy P Cripe; E Antonio Chiocca
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

4.  MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line.

Authors:  C Chetty; P Bhoopathi; S S Lakka; J S Rao
Journal:  Oncogene       Date:  2007-06-25       Impact factor: 9.867

5.  Local Cre-mediated gene recombination in vascular smooth muscle cells in mice.

Authors:  Susanne M Zadelaar; Lianne S M Boesten; Nuno M M Pires; Anita van Nieuwkoop; Erik A L Biessen; Wouter Jukema; Louis M Havekes; Bart J M van Vlijmen; Ko Willems van Dijk
Journal:  Transgenic Res       Date:  2006-02       Impact factor: 2.788

Review 6.  Matrix metalloproteases in head and neck cancer.

Authors:  Eben L Rosenthal; Lynn M Matrisian
Journal:  Head Neck       Date:  2006-07       Impact factor: 3.147

7.  Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer.

Authors:  Chandramu Chetty; Sajani S Lakka; Praveen Bhoopathi; Sateesh Kunigal; Roger Geiss; Jasti S Rao
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

8.  Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: relation to tumor phenotype and clinical outcome.

Authors:  Eleni Mylona; Christina Magkou; Ioanna Giannopoulou; George Agrogiannis; Sofia Markaki; Antonios Keramopoulos; Lydia Nakopoulou
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

Review 9.  MiR-21: an environmental driver of malignant melanoma?

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2015-06-27       Impact factor: 5.531

10.  TGF-β-elicited induction of tissue inhibitor of metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between Smad3, p38α, and ERK1/2.

Authors:  Suvi-Katri Leivonen; Konstantinos Lazaridis; Julie Decock; Andrew Chantry; Dylan R Edwards; Veli-Matti Kähäri
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.